Michael J Overman
M.D. Anderson Cancer Center · SWOG Cancer Research Network
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael J Overman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:33 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04800627 · Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid TumorM.D. Anderson Cancer Center · terminated · Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm · principal investigator
- Ph2NCT04729322 · Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-respondersM.D. Anderson Cancer Center · active not recruiting · Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 · principal investigator
- Ph2NCT04205968 · Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersSWOG Cancer Research Network · recruiting · Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 · principal investigator
- Ph2NCT04082572 · Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid CancersM.D. Anderson Cancer Center · completed · Locally Advanced Malignant Solid Neoplasm · principal investigator
- Ph1NCT02754856 · Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by SurgeryM.D. Anderson Cancer Center · completed · Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7 · principal investigator
- Ph1NCT02600949 · Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerM.D. Anderson Cancer Center · active not recruiting · Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A technological approach for performance status assessment in advanced cancer patientsR01CA243554 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2024 · $546,557 awarded in 2024Same name and institution; not confirmed by an ID
- Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.P50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2023 · $332,973 awarded in 2023Grant number is on one of their registry trials
- KRAS Muations in Plasma cfDNA as Predictor to Erolinib Response in Advanced Pancreatic CancerR21CA202487 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2016 to 2017 · $174,000 awarded in 2017Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT04205968
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:33 UTC. The ranking covers the 200 most relevant of 40 PubMed records, and a shared surname and initials can bring in a namesake. All 40 on PubMed
- 2,327 citationsRCR 75.2
- First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.J Clin Oncol · 2022615 citationsRCR 41.9
- 409 citationsRCR 9.0
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.Cancer Discov · 2016198 citationsRCR 5.4
- Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.J Clin Oncol · 2009189 citationsRCR 4.6
- Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.J Clin Oncol · 2023181 citationsRCR 14.4
- Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.J Clin Oncol · 2020115 citationsRCR 4.1
- The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.PLoS One · 2013114 citationsRCR 3.1
- Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.Support Care Cancer · 201483 citationsRCR 3.1
- 83 citationsRCR 2.7